Designed to be best in class.

Who it's all about.

We continuously engage with our customers to improve patient satisfaction. 

Customer Satisfaction Survey Results

1

99%
98%
98%
Product Satisifaction
On average, customers  responded with 99% product satisfaction. EMED is dedicated to developing products to serve patients and their infusion needs. 
On-time Delivery
The essential nature of our products means we prioritize on-time delivery. We're always looking for ways to deliver our products effectively.
Customer Service
On average, customers replied with 98% customer service satisfaction. We are committed to providing the best service to keep customers satisfied.

OPTFlow   Soft-Site   Dressing Survey Results

2

®

®

94%
97%
91%
Improvement of usability and patient comfort 
Easy Removal
94% of users reported that the new site dressing improves usability and patient comfort. 
97% of users reported that the site dressing was easy to remove from the skin.
Recommended
Over 90% of respondents recommend the Soft-Site to maximize patient comfort.
 
 

Trust the data.

OPTFlow and the SCIg60 Infuser work with a wide variety of immunoglobulin concentrations and viscosities.

OPTFlow Ig concentration range

20.0%
16.5%
10.0%

OPTFlow IgG viscosity range

2.88
8.12
10.08
14.71
Viscosity (cP) Compatibility Range

Designed for Higher Flow Rates

EMED OPTFlow needle sets have been engineered with a specific needle curvature designed to deliver higher flow rates while incorporating the coating technology for lower penetration force. The design exceeds drug requirements for a wide range of immunoglobulins. 

Time to explore flows and forces.

Flow Rate of 26ga Needle Sets 

3

EMED OPTFlow
US Competitor
4000
Flow rate (ml/hr)
2000
0
1
2
3
4

EMED OPTFlow administration sets  provide a solution for the increasing market demands of higher flow rates. EMED OPTFlow administration sets have higher maximum flow rates than subcutaneous device competitors.

Number of Injection Sites

Needle Penetration Force 

3

EMED Soft-Glide
US Competitor

EMED Soft-Glide needle design requires substantially less penetration force resulting in a virtually painless patient experience.

300%
Penetration Force
200%
100%
0%
Initial Puncture
Penetration Depth

Average Penetration Force During Insertion

3

EMED SoftGlide
Competitors
200%
100%
0%
Soft-Glide G27
Global
Competitor G27
Soft-Glide G24
US Competitor
G24

EMED Soft-Glide needle coating decreases penetration force by reducing friction between the needle surface and the skin maximizing patient comfort. 

Our approach

EMED recognizes the importance of partnering with leaders who have strategic advantages in their markets. For this reason, EMED offers infusion technology platforms to the pharmaceutical industry that can be tailored to meet specific clinical protocols. 

Global perspective.

EMED markets its devices under specific brand names through its international distribution networks. Our disruptive technology has earned EMED its international presence. 

Thinking outside the box

EMED promotes corporate responsibility through environmental, social, and governance means in addition to its core commitment of improving patients' lives through infusion therapy.

Research & Development

100M+

Device Development

 EMED has designed and developed over 100 million medical devices that contribute to the
well-being of patients.

10+

Patents 

EMED has secured 10 patents and continues to develop additional
intellectual property.

35% +

Reinvestment

EMED invests increasing amounts of capital year over year to be at the forefront of research and to improve infusion technology
based on patient needs.
 
Disclosures

All data displayed on this page has been gathered from independent testing and internal corporate documents. It is a violation of our Terms of Use to utilize, manipulate, or misconstrue this data. This data can only be used after explicit permission from EMED Technologies. Should EMED become aware of any violations or breaches of our Terms of Use, EMED will prosecute violators to the full extent of the law. If you are a patient, it is important that you discuss information about the benefits and risks of products with your doctor.

1. Data based on internal customer surveys from 2017-2019

2. Data based on internal customer survey from 2017

3. Based on bench testing (MM-057)

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Copyright © 2020 EMED Technologies Corporation. All Rights Reserved.

SR-0003_3.2